Nancy Chung-Welch Net Worth

Nancy Chung-Welch biography

Dr. Nancy Chung-Welch serves as Independent Director of the Company. Dr. Chung-Welch is currently an independent consultant advising life science companies and their institutional investors on life science companies, technologies and industries with an emphasis on the research product/tools market. Previously she was a Director, Business Development at Cell Signaling Technology and was Director, Business Development at Thermo Fisher Scientific and Technical Marketing Manager for Fisher Scientific. She has over 25 years of marketing and business development experience in the life sciences market. Dr. Chung-Welch has a balanced blend of business and technical/analytical strengths to provide sound foundation for technology/IP assessments and external partnerships. She has a strong record of domestic and international experience in business and customer needs analysis, technology assessment, licensing, distribution deals, partnerships, strategic alliances, strategic customer relationships, mergers/acquisitions. She previously served as Instructor in Surgery and Assistant in Physiology at Harvard Medical School and the Massachusetts General Hospital with expertise in basic science research, including cell biology, tissue culture, vascular physiology, genomics, proteomics, and lab automation applications. She is also a hands-on marketing executive and has conceptualized, launched, and managed products and services in the laboratory, medical, biotech/pharma, academic and government markets. She received her Ph.D. in Vascular Physiology and Cell Biology from Boston University.

What's Nancy Welch's mailing address?

Nancy's mailing address filed with the SEC is P.O. BOX 1572, , PEPPERELL, MA, 01463.

Insiders trading at Predictive Oncology

Over the last 5 years, insiders at Predictive Oncology have traded over $30,944 worth of Predictive Oncology stock and bought 417,770 units worth $148,589 . The most active insiders traders include Carl I. Schwartz, J Melville Engle et Charles Lee Sr Nuzum. On average, Predictive Oncology executives and independent directors trade stock every 71 days with the average trade being worth of $29,495. The most recent stock trade was executed by Robert L Myers on 25 September 2023, trading 1,667 units of POAI stock currently worth $1,584.

What does Predictive Oncology do?

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

Predictive Oncology executives and stock owners

Predictive Oncology executives and other stock owners filed with the SEC include:

• Dr. Carl I. Schwartz,
  CEO & Director
• Robert L. Myers,
  CFO & Sec.
• David Johnson,
  Senior Vice President - Operations
• Robert Myers,
  Chief Financial Officer
• J. Melville Engle,
  Chairman & CEO
• Richard L. Gabriel B.Sc, MBA,
  Sr. VP of R&D
• Gregory St.Clair,
  Independent Director
• Chuck Nuzum,
  Independent Director
• Nancy Chung-Welch,
  Independent Director
• Frank Mancuso,
  Director
• Timothy Krochuk,
  Director
• Ricardo Koenigsberger,
  Director
• Daniel Handley,
  Director
• H. Gabriel,
  Director
• J. Engle,
  Director
• Carl Schwartz,
  President, Chief Executive Officer, Director
• Dr. Arlette H. Uihlein FCAP, M.D.,
  Sr. VP of Regulatory Affairs & Quality
• Theresa Ferguson,
  Sr. Director of Marketing
• Dr. Julia Kirshner Ph.D.,
  Chief Scientific Officer
• Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D.,
  Sr. VP of Operations
• Pamela Bush M.B.A., Ph.D.,
  Sr. VP of Strategic Sales & Bus. Devel.
• Kevin Hungerford,
  VP of Sales & Marketing
• David Stewart Smith,
  
• Thomas J. Mc Goldrick,
  Director
• Gerald J Jr Vardzel,
  Director
• Veena Rao,
  Director
• Pamela S Prior,
  Director
• Charles Lee Sr Nuzum,
  Director
• Matthew Hawryluk,
  Director
• Christina Lee Md Jenkins,
  
• Raymond F Vennare,
  CHIEF EXECUTIVE OFFICER